Mehlika Dilek Altıntop | Medicinal Chemistry | Women Researcher Award

Dr. Mehlika Dilek Altıntop | Medicinal Chemistry| Women Researcher Award

Professor Doctorate of Anadolu University, Faculty of Pharmacy, Eskişehir, Turkey.

Mehlika Dilek Altıntop is a researcher specializing in the synthesis of bioactive compounds with therapeutic potential for cancer and metabolic disorders. Her work focuses on designing and evaluating enzyme inhibitors, particularly aldose reductase inhibitors for diabetes treatment. In pharmaceutical chemistry, she investigates new chemical entities with antimicrobial and anticancer activities. Altıntop also explores molecular hybridization to enhance biological activity and is involved in drug development, including the creation of innovative compounds like triazolothiadiazine derivatives. Her research contributes significantly to advancing treatment options and improving therapeutic outcomes.

Profile

Education:

Mehlika Dilek Altıntop’s educational journey began at İkieylül Elementary School, where she completed her primary education from 1991 to 1996. She then attended Eskişehir Anatolian High School for her secondary and high school education from 1996 to 2003. Pursuing higher education, she enrolled at Anadolu University, Faculty of Pharmacy, graduating with her undergraduate degree in 2007. She continued her academic career at Anadolu University, where she completed a Master’s Degree with Thesis in Pharmaceutical Chemistry at the Graduate School of Health Sciences between 2007 and 2009. Subsequently, she earned her Doctoral Degree in Pharmaceutical Chemistry from the same institution, graduating in 2012. Additionally, she possesses an excellent command of English, which complements her academic and professional expertise.

Academic Titles:

Prof. Dr. Mehlika Dilek Altıntop has had a distinguished career at Anadolu University, Faculty of Pharmacy. She began as a Research Assistant from 2010 to 2012, where she gained foundational experience in pharmaceutical research. She then advanced to the role of Research Assistant Doctor from 2012 to 2014, further deepening her expertise. Her career continued to progress as she took on the position of Assistant Professor Doctor from 2014 to 2015, during which she began to establish her reputation in the field. In 2015, she was promoted to Associate Professor Doctor, a role she held until 2020. Since 2020, Prof. Dr. Altıntop has served as a Professor Doctor at Anadolu University, where she continues to contribute significantly to the field of pharmacy through both her research and teaching activities. Her career reflects a consistent trajectory of academic growth and leadership.

Awards:

Prof. Dr. Mehlika Dilek Altıntop has received numerous accolades throughout her distinguished career. In 2007, she was honored with the Anadolu University Faculty of Pharmacy Championship Award and the Graduate Scholarship from The Scientific and Technological Research Council of Turkey. Her exceptional contributions were further recognized with the Anadolu University Science and Technology Encouragement Award and several Article Performance Awards from 2014 to 2018. She achieved the Gold and Platinum Article Performance Awards in 2015 and was named Outstanding Reviewer by the European Journal of Medicinal Chemistry in 2016. In 2019, she received the Turkish Pharmacists’ Association Academy of Pharmacy Encouragement Award. Prof. Altıntop was awarded the Anadolu University Academic Outstanding Success Award in 2020 and 2021 and recognized as the Outstanding Woman Researcher in Pharmaceutical Chemistry at VIWA 2021. Her invention, “Targeted Novel Triazolothiadiazine Derivatives for The Treatment of Lung Cancer,” earned a Silver Medal at ISIF’21. Her top-cited articles in Archiv der Pharmazie and Open Chemistry further highlight her impactful research.

 

Dr. Mehlika Dilek Altıntop’s research focuses on medicinal chemistry, with a particular emphasis on:

Mehlika Dilek Altıntop’s research is centered on the synthesis and development of bioactive compounds with significant therapeutic potential, particularly for cancer and metabolic disorders. Her work involves designing and evaluating enzyme inhibitors, such as aldose reductase inhibitors, to address conditions like diabetes. In pharmaceutical chemistry, she investigates new chemical entities and their pharmacological effects, including antimicrobial and anticancer properties. A key aspect of her research is molecular hybridization, where she combines different molecular scaffolds to enhance biological activity. Her focus on drug development includes the creation and testing of innovative drugs, exemplified by her work on triazolothiadiazine derivatives and other novel compounds. Altıntop’s contributions aim to advance therapeutic options and improve treatment outcomes across a range of medical conditions.

PUBLICATION TOP NOTES:

  1. “Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy”
    Altıntop, M.D., Ertorun, İ., Akalın Çiftçi, G., Özdemir, A.
    European Journal of Medicinal Chemistry, 2024
  2. “Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents”
    Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
    ACS Omega, 2024
  3. “Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents”
    Altıntop, M.D., Cantürk, Z., Özdemir, A.
    ACS Omega, 2023
  4. “Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy”
    Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
    ACS Omega, 2023
  5. “A new series of hydrazones as small-molecule aldose reductase inhibitors”
    Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
    Archiv der Pharmazie, 2023
  6. “A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer”
    Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
    Drug Development Research, 2023
  7. “Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action”
    Altıntop, M.D., Akalın Çiftçi, G., Yılmaz Savaş, N., Alataş, Ö., Özdemir, A.
    International Journal of Molecular Sciences, 2023
  8. “Microwave-assisted synthesis of a series of 4,5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency”
    Altıntop, M.D., Temel, H.E., Özdemir, A.
    Journal of the Serbian Chemical Society, 2023
  9. “Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer”
    Altıntop, M.D., Özdemir, A., Temel, H.E., Kaplancıklı, Z.A., Akalın Çiftçi, G.
    European Journal of Medicinal Chemistry, 2022

 

 

 

Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Dr Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Professor Doctorate, Anadolu University ,Turkey.

Ahmet ÖZDEMİR, born on July 24, 1972, in Muğla, Turkey, is a Professor of Pharmaceutical Chemistry at Anadolu University, where he has been a faculty member since 1997. He earned his undergraduate degree in Pharmacy from Anadolu University (1990-1994), followed by an M.Sc. in Pharmaceutical Chemistry (1995-1996) and a Ph.D. in the same field (1996-2004), with research focusing on the synthesis and biological activities of novel compounds. Dr. ÖZDEMİR has held various academic positions at Anadolu University, advancing from Research Assistant to Professor. He has also served in administrative roles, including Associate Director of Anadolu University Yunus Emre Vocational School and Vice Academic Director of the Open Education Faculty’s Department of Health Administration. His research is well-regarded, earning him multiple awards, including the Anadolu University Article Performance Award and the ISIF’21 Silver Medal for his work on targeted novel triazolothiadiazine derivatives for lung cancer treatment.

Profile:

Education

Prof. Dr. Ahmet Özdemir’s educational journey began at Salihli Cumhuriyet Elementary School, where he completed his primary education from 1978 to 1983. He continued his secondary education at Salihli 50. Yıl Secondary School from 1983 to 1986, and then attended Salihli High School from 1986 to 1989, where he completed his high school education. Prof. Dr. Özdemir pursued his undergraduate studies at Anadolu University Faculty of Pharmacy, graduating in 1994. He furthered his education with a Master’s Degree in Pharmaceutical Chemistry at Anadolu University’s Graduate School of Health Sciences from 1995 to 1996, where he completed his thesis. He continued at Anadolu University for his Doctoral Degree in Pharmaceutical Chemistry, which he achieved in 2004. Additionally, he possesses intermediate proficiency in English, which complements his academic background and research expertise.

Academic Titles

Prof. Dr. Ahmet Özdemir’s academic career at Anadolu University’s Faculty of Pharmacy spans several roles and achievements. He began his journey as a Research Assistant in 1997, a position he held until 2004. Following this, he advanced to the role of Research Assistant Doctor, continuing his work at the same institution from 2004 to 2005. Dr. Özdemir was then appointed as a Lecturer from 2005 to 2007, showcasing his growing expertise in the field. His contributions were recognized with a promotion to Assistant Professor Doctor, a role he embraced from 2007 to 2010. His exceptional work led to his promotion to Associate Professor Doctor, a position he held from 2010 to 2015. Since 2015, Prof. Dr. Özdemir has served as Professor Doctor, continuing to make significant contributions to the Faculty of Pharmacy and the broader academic community.

Awards

Prof. Dr. Ahmet Özdemir has received several prestigious awards for his academic and research contributions. In 2014, he was honored with the Anadolu University Article Performance Award. His outstanding achievements continued with the Anadolu University Gold Article Performance Award and the Anadolu University Platinum Article Performance Award in 2015. He maintained a high standard of excellence, receiving the Anadolu University Article Performance Award annually from 2016 to 2018. In 2019, Dr. Özdemir was recognized with the Anadolu University Academic Success Award. His consistent performance earned him the Anadolu University Article Performance Award again in 2020. Notably, in 2021, he was awarded the ISIF’21 Silver Medal for the invention titled “Targeted Novel Triazolothiadiazine Derivatives for the Treatment of Lung Cancer” at the 6th Istanbul International Inventions Fair (ISIF’21). This award was shared with Assoc. Prof. Dr. Belgin Sever, Prof. Dr. Mehlika Dilek Altintop, and Prof. Dr. Gülşen Akalın Çiftçi.

Research Focus

Prof. Dr. Ahmet Özdemir’s research is dedicated to the field of medicinal chemistry, with a keen focus on several key areas. He specializes in the synthesis of bioactive compounds, aiming to develop novel chemical entities with potential therapeutic uses, particularly targeting antifungal and antibacterial applications. His work in pharmaceutical chemistry involves investigating the physicochemical properties of these compounds, which has significant implications for drug design and efficacy. Dr. Özdemir also explores antimicrobial agents, focusing on the synthesis and evaluation of compounds designed to combat bacterial and fungal pathogens. In the realm of drug design and development, he examines structure-activity relationships to create effective and selective pharmaceutical agents. Additionally, his contributions extend to invention and innovation, where he develops novel chemical derivatives, such as triazolothiadiazine derivatives, for potential applications in treating diseases like lung cancer.

Publications

  1. “Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy”
    • Authors: Altıntop, M.D., Ertorun, İ., Akalın Çiftçi, G., Özdemir, A.
    • Year: 2024
  2. “Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents”
    • Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
    • Year: 2024
  3. “Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents”
    • Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
    • Year: 2023
  4. “Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy”
    • Authors: Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
    • Year: 2023
  5. “A new series of hydrazones as small-molecule aldose reductase inhibitors”
    • Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
    • Year: 2023
  6. “A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer”
    • Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
    • Year: 2023
  7. “Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action”
    • Authors: Altıntop, M.D., Akalın Çiftçi, G., Yılmaz Savaş, N., Alataş, Ö., Özdemir, A.
    • Year: 2023
  8. “Microwave-assisted synthesis of a series of 4,5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency”
    • Authors: Altıntop, M.D., Temel, H.E., Özdemir, A.
    • Year: 2023
  9. “Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer”
    • Authors: Altıntop, M.D., Özdemir, A., Temel, H.E., Kaplancıklı, Z.A., Akalın Çiftçi, G.
    • Year: 2022
  10. “A new series of thiosemicarbazone-based anti-inflammatory agents exerting their action through cyclooxygenase inhibition”
    • Authors: Altıntop, M.D., Sever, B., Akalın Çiftçi, G., Alataş, Ö., Özdemir, A.
    • Year: 2022